PSMA Specific Binding Proteins for Cancer Diagnosis and Treatment - US12611441B2
Summary
USPTO granted patent US12611441B2 to Navigo Proteins GmbH on April 28, 2026, covering binding proteins specific for prostate specific membrane antigen (PSMA) and their use in cancer diagnosis and treatment. The patent includes 15 claims and covers multimers, conjugates, and pharmacokinetics-modulating moieties. The invention has applications in both diagnostic and therapeutic contexts for cancers associated with PSMA expression.
“Binding proteins that are specific for prostate specific membrane antigen (PSMA), multimers thereof, and conjugates thereof are described.”
About this source
Granted patents in USPTO classification C07K, covering peptides, proteins, antibodies, and related biological molecules. Around 160 grants a month, each with the patent number, title, applicant, inventor names, and full abstract. Unlike published applications (which reveal in-progress research), grants are enforceable rights and signal what a company can now litigate or license. Watch this if you run an antibody or protein biologics program, advise on patent portfolio strategy for biologics companies, scout for licensing opportunities on recently granted claims, or track which research institutions are converting their early peptide work into issued patents.
What changed
USPTO granted patent US12611441B2 to Navigo Proteins GmbH for PSMA-specific binding proteins. The patent covers binding proteins, multimers, and conjugates specific for prostate specific membrane antigen, including those with diagnostically or therapeutically active components and pharmacokinetics-modulating moieties. The filing date was April 8, 2020, with 15 claims allowed.
For competitors developing PSMA-targeting cancer diagnostics or therapeutics, this patent establishes exclusive rights for Navigo Proteins in the US market for the claimed binding protein compositions and methods. Companies operating in the PSMA-targeted oncology space should conduct freedom-to-operate analyses to assess potential infringement risks.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PSMA specific binding proteins for cancer diagnosis and treatment
Grant US12611441B2 Kind: B2 Apr 28, 2026
Assignee
Navigo Proteins GmbH
Inventors
Eva Bosse-Doenecke, Manja Gloser-Bräunig, Florian Settele, Erik Fiedler, Ulrich Haupts
Abstract
Binding proteins that are specific for prostate specific membrane antigen (PSMA), multimers thereof, and conjugates thereof are described. Also described are PSMA binding proteins that include a diagnostically or therapeutically active component and/or a pharmacokinetics-modulating moiety, as well as methods for using the described PSMA binding proteins in medicine, for example, in diagnosis and therapy of cancer associated with PSMA expression.
CPC Classifications
A61K 38/17 C07K 14/47 G01N 33/6893
Filing Date
2020-04-08
Application No.
17602729
Claims
15
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.